AIM Immunotech Inc. (then Hemispherx Biopharma, Inc.) — Form 10-Q Summary
Reporting period: Three months ended March 31, 2019. The filing was made under Hemispherx Biopharma, Inc., the company’s name at the time. Financial amounts below are in U.S. dollars; unless noted, amounts are in thousands.
Business context
The company is a development-stage immuno-pharma business focused on Ampligen (rintatolimod) and Alferon N Injection. Ampligen was approved in Argentina for severe chronic fatigue syndrome, but required launch preparations remained outstanding; its U.S. application had previously received an FDA Complete Response Letter. Alferon is approved in the U.S. for genital warts, but manufacturing was on hold.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $0 | $56 |
| Operating loss | $2,926 | $2,570 |
| Net loss | $3,368 | $2,713 |
| Basic and diluted loss per share | $0.07 | $0.07 |
| Operating cash used | $1,457 | $2,542 |
- With no revenue in the quarter, revenue-based margins are not meaningful. R&D expense was $928, production costs $231, and general and administrative expense $1,767.
- Cash and cash equivalents were $2,394 and marketable securities $2,486 at March 31, for combined cash and securities of $4,880. Total assets were $15,965; stockholders’ equity was $3,930.
- Current liabilities were $2,087. Long-term liabilities included a $3,682 fair-value convertible note, a $2,267 sale-leaseback financing obligation, and $3,895 in redeemable warrants. The convertible note bears 10% interest and was amended to mature September 28, 2020.
- Financing activities provided $4,650, including $4,734 in net proceeds from stock sales and related transactions. Investing activities used $1,098.
Changes versus the prior period
- Net loss increased $655, or 24%, primarily due to higher G&A expense, the absence of a $223 building-sale gain recorded in 2018, and a $250 debt-discount write-off in 2019.
- Revenue fell from $56 to zero because clinical sites had purchased inventory in 2018 for patients in expanded-access programs.
- Operating cash use declined by $1,085, mainly because of collections of receivables. Cash and securities increased from $1,825 at December 31, 2018, supported by financing proceeds.
- Common shares outstanding rose from 48.7 million at year-end to 62.9 million at March 31. The company also issued Series B preferred shares through a rights offering; each preferred share was convertible into 5,000 common shares.
Outlook, risks and unusual items
- Funding and listing: Management said additional financing may be needed to develop products and restart manufacturing; no assurance of available financing was given. Equity at quarter-end was below the NYSE American’s stated $6 million minimum. Subsequent debt conversions and warrant exercises raised equity above that level by the filing date. The company also faced a low-share-price listing deficiency and planned to seek shareholder approval for a reverse split.
- Manufacturing and regulatory: The company estimated approximately $10 million would be needed to resume Alferon production, with no definitive restart timetable. FDA inspection and product-release approvals are required; failure to obtain them could materially harm operations. Ampligen manufacturing supply and regulatory approvals also remain risks.
- Development: Four Ampligen cancer trials were described as underway; additional trials were planned or in development, subject to funding and other conditions. The filing provides no financial or commercial guidance and cautions that clinical, regulatory, and commercialization outcomes are uncertain.
- Subsequent financing events: After quarter-end, approximately $1.8 million of convertible debt was converted to equity. On May 2, 2019, holders exercised 4.55 million warrants after an exercise-price reduction, generating approximately $682 in net proceeds and reducing warrant liabilities by about $404. Beginning May 8, approximately 14 million rights-offering warrants were exercised cashlessly, adding about $1.5 million to equity.
- Contingencies: The company disclosed a contract dispute with BioLife, including a $96,676 counterclaim, and a separate insurance lawsuit concerning a 2016 facility flood. Outcomes and any recoveries were uncertain.
Important facts for investors to verify
- Current cash, securities, operating cash burn, and the company’s expected financing needs.
- Progress on Ampligen’s clinical programs, U.S. regulatory requirements, Argentine launch preparations, and product supply.
- Funding, FDA inspection, and production timelines for restarting Alferon manufacturing, including the estimated $10 million cost.
- Post-quarter debt conversions and warrant exercises, resulting share count and dilution, and ongoing NYSE American listing compliance.
- Fair-value assumptions and potential cash-settlement exposure for warrant liabilities, as well as developments in the disclosed litigation.